Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Breast Neoplasms 60Prostatic Neoplasms 52Squamous Cell Carcinoma of Head and Neck 43Carcinoma, Non-Small-Cell Lung 39Head and Neck Neoplasms 37Lung Neoplasms 35Lymphoma 34Leukemia 22Brain Neoplasms 20Central Nervous System Neoplasms 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Glioblastoma 18Uterine Cervical Neoplasms 17Sarcoma 17Rectal Neoplasms 17Lymphoma, Follicular 16Esophageal Squamous Cell Carcinoma 16Esophageal Neoplasms 15Lymphoma, Large B-Cell, Diffuse 14Hodgkin Disease 14Burkitt Lymphoma 14Adenocarcinoma of Lung 13Oligodendroglioma 12Lymphoma, Non-Hodgkin 12Neoplasm Metastasis 11Astrocytoma 11Rhabdomyosarcoma 10Lymphoma, Large-Cell, Immunoblastic 10Neuroblastoma 9Nasopharyngeal Carcinoma 9

Interventions

pegaspargase 3merphos 3dexamethasone acetate 3dexamethasone 21-phosphate 3azathiopurine 3auricularum 3Vincristine 3Thioguanine 3Methotrexate 3Mercaptopurine 3Leucovorin 3Doxorubicin 3Dexamethasone 3Cytarabine 3Cyclophosphamide 3Calcium Dobesilate 3prednylidene 2deltacortene 2blinatumomab 2Radiotherapy 2Radiation 2Prednisone 2Prednisolone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Methylprednisolone 2Asparaginase 2calaspargase pegol 1asparaginase erwinia chrysanthemi recombinant 1Specimen Handling 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Radiotherapy × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡